Patient characteristics
| Characteristic . | No. . | % . |
|---|---|---|
| Median age, y (range) | 35 (8-62) | |
| Patients younger than 50 | 38 | 76 |
| Patients 50 or older | 12 | 24 |
| Sex | ||
| Male | 26 | 52 |
| Female | 24 | 48 |
| Disease severity | ||
| Very severe AA | 15 | 30 |
| Severe AA | 25 | 50 |
| Nonsevere AA | 10 | 20 |
| AA aetiology | ||
| Idiopathic | 39 | 78 |
| Drug-induced | 5 | 10 |
| Hepatitis | 4 | 8 |
| Pregnancy | 2 | 4 |
| Median interval Dx-HSCT, mo (range) | ||
| SIB | 6 (2-252) | |
| UD | 10 (4-137) | |
| Prior ATG treatment | ||
| Yes | 33 | 66 |
| No | 14 | 28 |
| Unknown | 3 | 6 |
| Donor type | ||
| Matched sibling | 21 | 42 |
| Unrelated | 29 | 58 |
| Stem cell source | ||
| BM | 24 | 48 |
| G-BM | 7 | 14 |
| PBSC | 14 | 27 |
| BM + PBSC | 5 | 10 |
| Transplantation period | ||
| 1999-2004 | 6 | 12 |
| 2005-2010 | 44 | 88 |
| Sorror score | ||
| 0-1 | 36 | 72 |
| 2 or more | 6 | 12 |
| Unknown | 8 | 16 |
| PNH clone at time of HSCT | 9/34 | 26 |
| CMV status | ||
| Donor+/recipient+ | 14 | 28 |
| Donor-/recipient- | 24 | 48 |
| Donor+/recipient- | 6 | 12 |
| Donor-/recipient+ | 6 | 12 |
| Total alemtuzumab dose | ||
| > 60 mg | 20 | 40 |
| ≤ 60 mg | 30 | 60 |
| Characteristic . | No. . | % . |
|---|---|---|
| Median age, y (range) | 35 (8-62) | |
| Patients younger than 50 | 38 | 76 |
| Patients 50 or older | 12 | 24 |
| Sex | ||
| Male | 26 | 52 |
| Female | 24 | 48 |
| Disease severity | ||
| Very severe AA | 15 | 30 |
| Severe AA | 25 | 50 |
| Nonsevere AA | 10 | 20 |
| AA aetiology | ||
| Idiopathic | 39 | 78 |
| Drug-induced | 5 | 10 |
| Hepatitis | 4 | 8 |
| Pregnancy | 2 | 4 |
| Median interval Dx-HSCT, mo (range) | ||
| SIB | 6 (2-252) | |
| UD | 10 (4-137) | |
| Prior ATG treatment | ||
| Yes | 33 | 66 |
| No | 14 | 28 |
| Unknown | 3 | 6 |
| Donor type | ||
| Matched sibling | 21 | 42 |
| Unrelated | 29 | 58 |
| Stem cell source | ||
| BM | 24 | 48 |
| G-BM | 7 | 14 |
| PBSC | 14 | 27 |
| BM + PBSC | 5 | 10 |
| Transplantation period | ||
| 1999-2004 | 6 | 12 |
| 2005-2010 | 44 | 88 |
| Sorror score | ||
| 0-1 | 36 | 72 |
| 2 or more | 6 | 12 |
| Unknown | 8 | 16 |
| PNH clone at time of HSCT | 9/34 | 26 |
| CMV status | ||
| Donor+/recipient+ | 14 | 28 |
| Donor-/recipient- | 24 | 48 |
| Donor+/recipient- | 6 | 12 |
| Donor-/recipient+ | 6 | 12 |
| Total alemtuzumab dose | ||
| > 60 mg | 20 | 40 |
| ≤ 60 mg | 30 | 60 |